Description
The $325 billion-a-year pharmaceutical business is America’s toughest and one of its most profitable. It’s riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all the hurdles to get to human testing.
Simon Jennings –
Barry Werth’s new book does for the world of biotech drug development what The Soul of a New Machine did for the dawn of the computer age. It presents an exciting narrative about the business of bringing new products to market.